SCHEMBL20918264

SCHEMBL20918264

Cc1cccc(-c2oc3c(C)cccc3c(=O)c2C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.56
NPC1 O15118 2/20 0.56
MAPT P10636 2/20 0.56
RAB9A P51151 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HTT P42858 2/20 0.56
MEN1 O00255 1/20 0.56
HPGD P15428 1/20 0.56
KMT2A Q03164 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MCL1 Q07820 1/20 0.46
IP6K1 Q92551 1/20 0.43
IP6K3 Q96PC2 1/20 0.43
IP6K2 Q9UHH9 1/20 0.43
LDHA P00338 1/20 0.40
LDHB P07195 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
TTR P02766 1/20 0.40
RXRA P19793 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31723147 1.00 KDM4E (0.56) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL14266219 0.89 ALDH1A1 (0.58) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL28895627 0.88 MEN1 (0.48) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL31723178 0.88 MEN1 (0.48) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL31723146 0.85 ALDH1A1 (0.52) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL20918077 0.85 ALDH1A1 (0.52) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL20918211 0.84 MCL1 (0.46) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL31723134 0.84 MCL1 (0.46) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL20918209 0.84 MEN1 (0.46) KDM4ENPC1MAPTRAB9AALDH1A1
SCHEMBL31723170 0.84 MEN1 (0.46) KDM4ENPC1MAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699174-B1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2025-11-12 EP claimed
US-11850230-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2023-12-26 US claimed
US-20230099574-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2023-03-30 US claimed
US-11504349-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2022-11-22 US claimed
EP-3699174-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2020-08-26 EP claimed
US-20200246304-A1 Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same ILAB (KR) 2020-08-06 US claimed
CN-111315730-A Composition for preventing or treating tumor necrosis factor-related diseases comprising novel derivative as active ingredient and method for inhibiting tumor necrosis factor activity using the same 艾伊莱布 2020-06-19 CN claimed
WO-2019078452-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME 가톨릭대학교 산학협력단 2019-04-25 WO claimed
EP-3699174-B1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2025-11-12 EP disclosed
US-11850230-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2023-12-26 US disclosed
US-20230099574-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2023-03-30 US disclosed
US-11504349-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2022-11-22 US disclosed
EP-3699174-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2020-08-26 EP disclosed
US-20200246304-A1 Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same ILAB (KR) 2020-08-06 US disclosed
CN-111315730-A Composition for preventing or treating tumor necrosis factor-related diseases comprising novel derivative as active ingredient and method for inhibiting tumor necrosis factor activity using the same 艾伊莱布 2020-06-19 CN disclosed
WO-2019078452-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME 가톨릭대학교 산학협력단 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11850230-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same TNF, NFKBIA, TRAF6 KDM4E 2226/4885NPC1 2711/4885MAPT 2554/4885
US-20230099574-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME TNF, NFKBIA, TRAF6 KDM4E 2226/4885NPC1 2711/4885MAPT 2554/4885
US-20200246304-A1 Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same TNF, NFKBIA, TRAF6 KDM4E 2226/4885NPC1 2711/4885MAPT 2554/4885
US-11504349-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same TNF, NFKBIA, TRAF6 KDM4E 2226/4885NPC1 2711/4885MAPT 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.